newsfilter
← Latest News
PR Newswire·

Evofem Biosciences Reports Year-End 2022 Financial Results and Provides Corporate Update

-- Net product sales more than doubled in 2022 vs. prior year -- -- Reduced total operating expenses by $74.1 million in 2022 vs. 2021, exceeding stated goal -- -- Evofem targeting EBITDA break-even by year-end 2023